Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
Meiqin Chen, Chenlu Wang, Yinan Lin, Yanbing Chen, Wenting Xie, Xiaoting Huang, Fan Zhang, Congrui Fu, Kai Zhuang, Tingting Zou, Dan Can, Huifang Li, Shengxi Wu, Ceng Luo, Jie Zhan. Dorsal raphe nucleus-hippocampus serotonergic circuit underlies the depressive and cognitive impairments in 5×FAD male mice. Translational neurodegeneration. vol 13. issue 1. 2024-07-24. PMID:39044270. |
the serotonergic system plays crucial roles in both ad and depression. |
2024-07-24 |
2024-07-26 |
mouse |
Lidan Yi, Jing Chen, Sini Li, Wei Cui, Jianhe Li, Liubao Peng, Ciyan Pen. Efficacy and safety of Chinese patent medicines combined with antidepressants for treatment of depression in adults: A multiple-treatment meta-analysis. Journal of psychiatric research. vol 176. 2024-06-15. PMID:38878648. |
combinations of chinese patent medicines (cpm) with antidepressants (including selective serotonin reuptake inhibitors (ssri), selective serotonin-norepinephrine reuptake inhibitors (snri), tricyclic antidepressants (tca), and noradrenergic and specific serotonergic antidepressants (nassa)) are frequently utilized for treating depression in adults. |
2024-06-15 |
2024-06-18 |
Not clear |
Mellar P Davi. Novel therapies for nausea and vomiting in advanced illness and supportive cancer care. Palliative care and social practice. vol 18. 2024-06-10. PMID:38855566. |
mirtazapine is a noradrenergic and specific serotonergic antidepressant that has been used for multiple symptoms besides depression. |
2024-06-10 |
2024-06-14 |
Not clear |
Xiao Liu, Stephen J Rea. Development of a multivariate prediction model for antidepressant resistant depression using reward-related predictors. Frontiers in psychiatry. vol 15. 2024-04-09. PMID:38590792. |
individuals with depression who do not respond to two or more courses of serotonergic antidepressants tend to have greater deficits in reward processing and greater internalizing symptoms, yet there is no validated self-report method to determine the likelihood of treatment resistance based on these symptom dimensions. |
2024-04-09 |
2024-04-11 |
Not clear |
Zarah R Haniff, Mariia Bocharova, Tim Mantingh, James J Rucker, Latha Velayudhan, David M Taylor, Allan H Young, Dag Aarsland, Anthony C Vernon, Sandrine Thure. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases. Pharmacology & therapeutics. 2024-04-07. PMID:38583670. |
in this context, psilocybin, a serotonergic agonist with rapid-acting antidepressant properties has the potential to ameliorate intersecting pathophysiological processes relevant for both major depression and neurodegenerative diseases. |
2024-04-07 |
2024-04-10 |
Not clear |
Nina Nitzan Soto, Patricia Gaspar, Alberto Bacc. Not Just a Mood Disorder─Is Depression a Neurodevelopmental, Cognitive Disorder? Focus on Prefronto-Thalamic Circuits. ACS chemical neuroscience. 2024-04-05. PMID:38580316. |
we discuss how early life insults affecting the serotonergic system could be important in the alterations of these local and long-range circuits, thus favoring the emergence of neurodevelopmental disorders, such as depression. |
2024-04-05 |
2024-04-10 |
Not clear |
David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harri. Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of psychopharmacology (Oxford, England). 2024-03-23. PMID:38520045. |
effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. |
2024-03-23 |
2024-03-26 |
human |
Paul J Fitzgeral. Affective disorders and the loudness dependence of the auditory evoked potential: Serotonin and beyond. Neuroscience letters. 2024-03-18. PMID:38499279. |
it has been suggested that increased values of the ldaep indicate low central serotonergic neurotransmission, further implicating this eeg measure in depression. |
2024-03-18 |
2024-03-21 |
Not clear |
Svenja Bremshey, Juliana Groß, Kim Renken, Olivia Andrea Massec. The role of serotonin in depression-A historical roundup and future directions. Journal of neurochemistry. 2024-03-13. PMID:38477031. |
these new tools in combination with systemic applications, will in the future provide a deeper understanding of the serotonergic dynamics in depression. |
2024-03-13 |
2024-03-15 |
Not clear |
Laura Staal, Torsten Plösch, Theodora Kunovac Kallak, Inger Sundström Poromaa, Bregje Wertheim, Jocelien D A Olivie. Sex-Specific Transcriptomic Changes in the Villous Tissue of Placentas of Pregnant Women Using a Selective Serotonin Reuptake Inhibitor. ACS chemical neuroscience. 2024-02-29. PMID:38421943. |
in this study, we aim to elucidate how disturbances in the maternal serotonergic system affect the villous tissue of the placenta by assessing whole transcriptomes in the placentas of women with healthy pregnancies and women with depression and treated with the ssri fluoxetine during pregnancy. |
2024-02-29 |
2024-03-03 |
Not clear |
Débora Copa, David Erritzoe, Bruna Giribaldi, David Nutt, Robin Carhart-Harris, Enzo Tagliazucch. Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. Journal of affective disorders. 2024-02-29. PMID:38423367. |
psilocybin is a serotonergic psychedelic drug under assessment as a potential therapy for treatment-resistant and major depression. |
2024-02-29 |
2024-03-03 |
Not clear |
Kurt A Jellinge. The pathobiology of depression in Huntington's disease: an unresolved puzzle. Journal of neural transmission (Vienna, Austria : 1996). 2024-02-13. PMID:38349403. |
while it was believed that depression in hd is due to psychosomatic factors in view of the fatal disease, studies in transgenic models of hd demonstrated molecular changes including neurotrophic and serotonergic dysregulation and disorders of the hypothalamic-pituitary-adrenal axis inducing depression-like changes. |
2024-02-13 |
2024-02-15 |
Not clear |
Yanan Li, Luxi Li, Shanshan Wei, Jia Yao, Benhui Liang, Xue Chu, Lei Wang, Hui Liu, Dehua Liao, Daotong Liu, Pei Jian. Integrating transcriptomics and metabolomics to elucidate the mechanism by which taurine protects against DOX-induced depression. Scientific reports. vol 14. issue 1. 2024-02-01. PMID:38302509. |
the various pathways identified in this study, such as the serotonergic synapse and the inflammatory mediator regulation of trp channels, may be key regulatory pathways related to depression and antidepressant effects. |
2024-02-01 |
2024-02-04 |
mouse |
Tuane Bazanella Sampaio, Marissa Giovanna Schamne, Jean Rodrigo Santos, Marcelo Machado Ferro, Edmar Miyoshi, Rui Daniel Predige. Exploring Parkinson's Disease-Associated Depression: Role of Inflammation on the Noradrenergic and Serotonergic Pathways. Brain sciences. vol 14. issue 1. 2024-01-26. PMID:38275520. |
exploring parkinson's disease-associated depression: role of inflammation on the noradrenergic and serotonergic pathways. |
2024-01-26 |
2024-01-28 |
Not clear |
Tuane Bazanella Sampaio, Marissa Giovanna Schamne, Jean Rodrigo Santos, Marcelo Machado Ferro, Edmar Miyoshi, Rui Daniel Predige. Exploring Parkinson's Disease-Associated Depression: Role of Inflammation on the Noradrenergic and Serotonergic Pathways. Brain sciences. vol 14. issue 1. 2024-01-26. PMID:38275520. |
thus, through this comprehensive literature review, we shed light on the noradrenergic and serotonergic impairment linked to depression in pd, focusing on the putative involvement of inflammatory mechanisms. |
2024-01-26 |
2024-01-28 |
Not clear |
Bedia Samanci, Sonny Tan, Stijn Michielse, Mark L Kuijf, Yasin Teme. THE HABENULA IN PARKINSON'S DISEASE: ANATOMY, FUNCTION, AND IMPLICATIONS FOR MOOD DISORDERS - A NARRATIVE REVIEW. Journal of chemical neuroanatomy. 2024-01-18. PMID:38237746. |
degeneration of serotonergic neurons in brainstem raphe nuclei have been linked to depression and anxiety. |
2024-01-18 |
2024-01-21 |
Not clear |
Volkan Uzungil, Sandra Luza, Carlos M Opazo, Isaline Mees, Shanshan Li, Ching-Seng Ang, Nicholas A Williamson, Ashley I Bush, Anthony J Hannan, Thibault Renoi. Phosphoproteomics implicates glutamatergic and dopaminergic signalling in the antidepressant-like properties of the iron chelator deferiprone. Neuropharmacology. 2024-01-06. PMID:38184274. |
polymorphisms of the serotonin transporter (5-htt) gene have been linked to depression (when combined with stressful life events) and to altered response to selective serotonergic reuptake inhibitors. |
2024-01-06 |
2024-01-09 |
mouse |
Richard A Glennon, Mal Gorzata Duka. α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant. ACS pharmacology & translational science. vol 6. issue 12. 2023-12-14. PMID:38093842. |
hallucinogenic tryptamines (that is, serotonergic psychedelic agents) are now in vogue as novel and exciting chemotherapeutics for the treatment of various neuropsychiatric disorders, including treatment-resistant depression and anxiety. |
2023-12-14 |
2023-12-17 |
Not clear |
Przemysław J Danek, Władysława A Danie. The Novel Atypical Antipsychotic Lurasidone Affects Cytochrome P450 Expression in the Liver and Peripheral Blood Lymphocytes. International journal of molecular sciences. vol 24. issue 23. 2023-12-09. PMID:38069119. |
lurasidone is a novel atypical antipsychotic drug acting on dopaminergic, serotonergic and noradrenergic receptors; it is applied for the long-term treatment of schizophrenia and depression in patients with bipolar disorders. |
2023-12-09 |
2023-12-17 |
rat |
Minsoo Kim, Woonhee Kim, ChiHye Chun. The neural basis underlying female vulnerability to depressive disorders. Animal cells and systems. vol 27. issue 1. 2023-12-01. PMID:38023591. |
furthermore, other brain circuits involving the dopaminergic center (ventral tegmental area) and the serotonergic center (dorsal raphe nucleus), along with their respective projections, have shown sex differences in relation to depression. |
2023-12-01 |
2023-12-07 |
Not clear |